The effect of Aripiprazole on obsessive compulsive symptoms

Phase 3

Conditions: Obsessive-compulsive symptoms in patients with schizophrenia.
Schizophrenia

Registration Number: IRCT20181001041192N1

Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 40

Inclusion Criteria

Women and men admitted to the psychiatric wards of the Zare hospital in Sari, who were between the ages of 18 and 65.
Patients diagnosed with schizophrenia based on DSM-5 criteria that simultaneously had obsessive-compulsive symptoms.
If they received medications such as mood-stabilizers and anti-depressant medications along with their antipsychotic regimen, their dosage was fixed one month before the study began and during the study.

Exclusion Criteria

The presence of psychiatric disorders in the first axis, as bipolar disorder or major depressive disorder.
Substance dependency (based on DSM-5, as well as 6-month relapse or substance abuse in the three months prior to the onset of the study or positive urine specimen testing at the start of the study).
Patients treated with ECT in the last six months.
Individuals with suicidal/homicidal ideas or attempts at the start of the study or 6 months before the start of the study.
People with intellectual disabilities.
Pregnant or lactating women.
Patients with neurological disorders such as dementia, delirium, uncontrolled seizure and head trauma.
People with uncontrolled underlying conditions such as cardiovascular disease, liver and kidney failure, various malignancies, endocrine disorders and hematological disorders.
Patients who have already been treated with aripiprazole.
Patients who had a history of allergy or intolerance to aripiprazole.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Obsessive-compulsive symptoms in patients with schizophrenia. Timepoint: The beginning of the study and the end of the fourth and sixth weeks. Method of measurement: by the Yale-Brown Obsessive Scale (Y-BOCS).

Secondary Outcome Measures

Name	Time	Method
Global Assessment of Functioning. Timepoint: At the beginning of the study, the end of the fourth and sixth weeks. Method of measurement: Global Assessment of Functioning Scale (GAF).;Positive and negative and general Symptoms. Timepoint: At the beginning of the study, the end of the fourth and sixth weeks. Method of measurement: Positive and Negative Syndrome Scale (PANSS).;Assess extrapyramidal side effects. Timepoint: Weekly. Method of measurement: Abnormal Involuntary Movement Scale(AIMS), Barnes Akathisia Rating Scale (BARS), Simpson-Angus Scale (SAS).